Indication: CAP

ZINFORO®: Mode of Action (MOA)

How does Zinforo® exert bactericidal activity?

Zinforo® exerts potent bactericidal activity in cSSTI against resistant isolates  with high-binding affinity to mutated beta-lactam-binding proteins3-8

It enforces bactericidal activity in CAP against resistant isolates with high-binding affinity in Streptococcus pneumoniae3-5


Adapted from Garrison MW, et al. 2012.

Find out more ▷

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; MRSA, Methicillin-resistant Staphylococcus aureus.
 

References: 
1. Zinforo® (ceftaroline fosamil). Local Product Document of Ceftaroline. LPDZIN072021. 
2. Rosanova MT, et al. Ther Adv Infect Dis. 2019;6:2049936118808655.
3. Garrison MW, Kawamura NM, Wen MM. Expert Rev Anti Infect Ther. 2012;10:1087-1103. 
4. Laudano JB. J Antimicrob Chemother. 2011;66(suppl 3):iii11-iii18.
5. Drusano GL. J Antimicrob Chemother. 2011;66(suppl 3):iii61-iii67.
6. Casapao AM, Davis SL, Barr VO, et al. Antimicrob Agents Chemother. 2014;58:2541-2546.
7. Ishikawa T, Matsunaga N, Tawada H, et al. Bioorg Med Chem. 2003;11:2427-2437.
8. Moisan H, Pruneau M, Malouin F. J Antimicrob Chemother. 2010;65:713-716.

 

 

PP-ZFO-IND-0352 22 February 2022
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioners, or a hospital or a laboratory.